|
業務類別
|
Biotechnology |
|
業務概覽
|
MeiraGTx Holdings PLC is a clinical-stage gene therapy company. It focuses on the eye, salivary gland, and central nervous system disorders. The company's pipeline products include AAV-CNGB3, AAV-CNGA3 and AAV-RPGR, and others. Geographically, it operates in the United States, the United Kingdom, and European Union. |
| 公司地址
| 450 East 29th Street, 14th Floor, New York, NY, USA, 10016 |
| 電話號碼
| +1 646 860-7985 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.meiragtx.com |
| 員工數量
| 425 |
| Dr. Stuart Naylor, PhD |
Chief Development Officer |
美元 501.17K |
30/04/2025 |
| Dr. Alexandria Forbes, PhD |
President, Chief Executive Officer and Director |
美元 840.00K |
30/04/2025 |
| Dr. Robert K. Zeldin, M.D. |
Chief Medical Officer |
-- |
30/04/2025 |
| Mr. Richard Giroux |
Chief Accounting Officer, Chief Operating Officer and Chief Financial Officer |
美元 714.00K |
30/04/2025 |
| Mr. Robert J. Wollin |
General Counsel and Secretary |
-- |
30/04/2025 |
|
|
| Dr. Thomas E. Shenk, PhD |
Independent Director |
30/04/2025 |
| Ms. Nicole Seligman |
Independent Director |
30/04/2025 |
| Dr. Alexandria Forbes, PhD |
President, Chief Executive Officer and Director |
30/04/2025 |
| Dr. Keith R. Harris, PhD |
Chairman of the Board |
30/04/2025 |
| Dr. Ellen Hukkelhoven, PhD |
Director |
30/04/2025 |
| Lord Neil Mendoza |
Independent Director |
30/04/2025 |
| Dr. Debra Yu, M.D. |
Independent Director |
30/04/2025 |
|
|
|
|
